REATA PHARMACEUTICALS, INC. Reata Pharmaceuticals, Inc. announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company's research and development functions. Dr. Patni brings over 23 years of global product development experience, including 18 clinical programs in the cardiology, diabetology, hepatology, neurology, and benign hematology therapeutic areas.
Prior to joining Reata, Dr. Patni was Chief Medical Officer (CMO) at Global Blood Therapeutics from 2020 to 2023. Prior to that time, he was CMO at Portola Pharmaceuticals and Adamas Pharmaceuticals. Early in his career, Dr. Patni worked at Pfizer, Roche, and Actelion, where he held positions of increasing responsibility.
His proven track record in fostering successful team efforts at these different companies contributed to the approval of 10 medicines from the U.S. Food and Drug Administration, European Medicines Agency, and other regulatory agencies. Dr. Patni received his MD degree from the Mount Sinai School of Medicine in New York City, as part of an accelerated BS/MD program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician before joining industry.
